February 09, 2012

CHEST PHYSICIANS NOW SUGGEST EARLY INTERVENTION FOR CERTAIN BLOOD CLOTS IN DVT

NORTHBROOK, Ill., July 29 /PRNewswire/ -- The American College of Chest Physicians (ACCP) has published new evidence-based clinical guidelines for physicians that for the first time suggest the use of pharmacomechanical thrombolysis for acute iliofemoral deep vein thrombosis (DVT) in conjunction with anticoagulation drug therapy. The new guidelines appear in the July supplement to the CHEST journal.

"This is a major change in the recommendations for the care of these patients with extensive DVT, and represents a major advance in treatment. Adopting an initial strategy of thrombus removal will improve the quality of life of these patients and potentially avoid recurrent DVT in the future," stated Anthony J. Comerota, MD, FACS, FACC, Director of the Jobst Vascular Center and Adjunct Professor of Surgery, University of Michigan.

"The recommendation to treat certain cases of acute DVT with pharmacomechanical thrombolysis adds an important tool to help treat the acute problem as well as to minimize the long-term disability of post-thrombotic syndrome (PTS) in patients," added Katharine L. Krol, MD, Director, Vascular Interventional Radiology, CorVasc MDs, Indianapolis, IN and recent past president of the Society of Interventional Radiology (SIR).

The new Venous Thromboembolic (VTE) Disease guidelines represent an evolution from the previous ACCP standard which recommended the use of anticoagulation drug therapy alone for the treatment of DVT. For complete information on the new ACCP VTE Guidelines, visit http://www.TheNewGuidelines.org.

While anticoagulation alone mitigates the risk of clot propagation and pulmonary embolism, it often fails to clear the blockage. This residual thrombus can lead to venous hypertension, valvular insufficiency, skin ulcerations and post-thrombotic syndrome.

"The publication of the new 2008 ACCP guidelines suggesting the use of pharmacomechanical thrombolysis clearly establishes a new standard for thrombolytic therapy. We believe the Trellis(R) Isolated Pharmacomechanical Thrombolysis method provides the best available combination of safety and efficacy," remarked Scott Cramer, President and CEO of Bacchus Vascular, Inc.

Isolated pharmacomechanical thrombolysis using the Trellis Peripheral Infusion System from Bacchus Vascular, Inc. to deliver thrombolytic directly into a desired treatment segment has proven to be a rapid, effective and safe method of treating patients with acute DVT. The Trellis device is the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment.

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com.

For complete information on the new ACCP VTE Guidelines, visit: http://www.TheNewGuidelines.org.

SOURCE Bacchus Vascular, Inc.